The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.
Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.
The companies will offer customers access to their technologies and services for cancer image analysis and tissue-based biomarker research and development.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.
NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.
NEW YORK (GenomeWeb) – Definiens announced today that it has raised €15 million ($20.4 million) in a private round of financing that will support the firm's efforts to expand its business into digital tissue diagnostics.
NEW YORK (GenomeWeb News) – Definiens and Metamark Genetics today announced a multiyear agreement for use of Definiens' image analysis product for Metamark's prostate cancer prognostic test.
Vermillion said this week that at its annual meeting on March 21, shareholders elected Robert Goggin to the company's board of directors.
Quantitative digital pathology firm Definiens has appointed a new advisory board to provide independent advice on trends in tissue diagnostics and clinical digital pathology.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.